



December 30, 2018

Via e-mail: AGO.highcostprescriptiondrugs@vermont.gov

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. s. 4637

To Whom It May Concern:

Teva Pharmaceuticals USA, Inc. (“Teva”) submits this information pursuant to 18 V.S.A. s. 4637.

On December 28, 2018, Teva released the following generic prescription drug to the commercial market:

NDC	Product Description	WAC
00591-2416-30	CINACALCET HCL 30MG TABLETS 30	\$696.99
00591-2417-30	CINACALCET HCL 60MG TABLETS 30	\$1,393.98
00591-2418-30	CINACALCET HCL 90MG TABLETS 30	\$2,090.97

Teva reserves any and all rights that it may have to challenge the governing statute, its interpretation, or the application of it to Teva.

Thank you for your consideration.

Sincerely,

/s/Jason B. Daly

Jason B. Daly
VP & General Counsel | NA Commercial & Generics
Teva Pharmaceuticals USA, Inc.